Thyquidity (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending
Thyquidity (Levothyroxine Sodium) by Jerome Stevens: FDA Orange Book LOE 2031-08-06, 7 AB generics, $614K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Jerome Stevens |
| FDA Application & Pathway | N214047 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2031-08-06 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $614K |
| 2024 Medicare Part D Spend | $257K |
| 2024 Medicaid Spend | $357K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.9% 2-yr change) |